IRAK1 and nasopharyngeal carcinoma: In addition, pacritinib has also been reported to reduce chemotherapy resistance in nasopharyngeal carcinoma, mainly by regulating the phosphorylation level of IRAK1, thereby inhibiting the expression of S100A9 and reducing the patients with nasopharyngeal carcinoma resistance to paclitaxel (Liu et al., 2021).